Landmark Study at UHN Leads to Safer Treatments

We are delighted to announce the publication of the FIBRES Trial, a multi-centered study that was led by members of the Department of Anesthesia and involved a large group of collaborators from across the country. This landmark study showed that fibrinogen concentrate, a new pathogen-reduced purified blood product, is as effective and safe as the older standard of care, cryoprecipitate (which has logistical and safety issues).

This important finding is rapidly changing practice across Canada and will likely influence practice around the world.

Congratulations to Dr. Keyvan Karkouti, Chief of Anesthesia at UHN-Toronto General Hospital, co-Principal investigator in the study; to Dr. Jeannie Callum, blood transfusion specialist at Sunnybrook Health Sciences Centre; and to Dr. Michael Farkouh, who was the lead cardiologist on the trial. Dr. Karkouti’s research is supported, in part, by a Merit Award from the Department of Anesthesia, University of Toronto.

We invite you to read the full JAMA publication and news article.